Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04667377 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 387
- Enrollment target
NCT04667377: Completed Phase 2 study, sponsored by Boehringer Ingelheim.
NCT04667377 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 387 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (191% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04667377, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 387 participants
- Enrollment target
Study Summary
This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate. The purpose of this study is to find out whether a medicine called BI 456906 helps people lose weight. Participants are put into 5 groups by chance. 4 groups get different doses of BI 456906. The fifth group gets placebo. Participants get BI 456906 or placebo as injections under the skin once a week. Placebo injections look like BI 456906 injections but do not contain any medicine. Participants are in the study for about a year. During this time, there are about 20 in-person visits to the study site. At the study site visits, doctors measure participants' body weight. Results are compared between the BI 456906 groups and the placebo group. The doctors also regularly check the general health of the participants.
Primary Outcome
Percentage change in body weight from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline body weight as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures, an unstructured covariance matrix to model within subject measurements, adjusted mean (stand
Interventions
- DRUG Placebo
- DRUG BI 456906
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2021-03-08 |
| Est. Completion | 2022-10-07 |
| Phase | Phase 2 |
What the finished NCT04667377 record still lists
NCT04667377 is an interventional study that assigns participants to a tested intervention. The registered 387 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (191% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04667377 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04667377 about?
NCT04667377 is a clinical study titled "A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight". This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate. The purpose of this study is to find out whether a medicine called BI 456906 helps people lose weight. Par...
What is the current status of trial NCT04667377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 387 participants. The study started on 2021-03-08. Estimated completion is 2022-10-07.
What interventions are being tested in trial NCT04667377?
The interventions under investigation include: Placebo (DRUG), BI 456906 (DRUG).
Who is sponsoring clinical trial NCT04667377?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04667377's enrollment target sits among peer trials
387 109th of 2000 higher than 1,892 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03761108 · 387 participants · Phase 1
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- NCT05572632 · 387 participants · NA
Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD
- NCT06917079 · 387 participants · Phase 1
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- NCT04092010 · 388 participants · NA
Improving Preschool Outcomes by Addressing Maternal Depression in Head Start
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI